ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 195 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 1.55 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,117 | -49.8% | 458,100 | -3.8% | 0.01% | -40.0% |
| Q2 2023 | $10,193 | -41.0% | 476,300 | +11.4% | 0.02% | -34.8% |
| Q1 2023 | $17,287 | -21.5% | 427,464 | -9.7% | 0.02% | -23.3% |
| Q4 2022 | $22,013 | -99.9% | 473,200 | +1.1% | 0.03% | -11.8% |
| Q3 2022 | $24,275,000 | -5.4% | 468,000 | -13.8% | 0.03% | +13.3% |
| Q2 2022 | $25,658,000 | -40.6% | 542,800 | -10.6% | 0.03% | -41.2% |
| Q1 2022 | $43,213,000 | -19.1% | 607,100 | -15.0% | 0.05% | -22.7% |
| Q4 2021 | $53,423,000 | +24.3% | 714,400 | -5.6% | 0.07% | +17.9% |
| Q3 2021 | $42,982,000 | +22.4% | 756,585 | -5.2% | 0.06% | +27.3% |
| Q2 2021 | $35,108,000 | -20.9% | 797,728 | -11.4% | 0.04% | -20.0% |
| Q1 2021 | $44,398,000 | +2.0% | 900,200 | -12.9% | 0.06% | +17.0% |
| Q4 2020 | $43,527,000 | -7.6% | 1,033,900 | +0.5% | 0.05% | 0.0% |
| Q3 2020 | $47,108,000 | -0.5% | 1,029,000 | +9.1% | 0.05% | +14.6% |
| Q2 2020 | $47,343,000 | +4.5% | 942,900 | +7.1% | 0.04% | -6.8% |
| Q1 2020 | $45,289,000 | +0.2% | 880,600 | +20.4% | 0.04% | +25.7% |
| Q4 2019 | $45,198,000 | +13.5% | 731,600 | +10.4% | 0.04% | +2.9% |
| Q3 2019 | $39,827,000 | -14.2% | 662,900 | +20.5% | 0.03% | -17.1% |
| Q2 2019 | $46,434,000 | -24.7% | 550,300 | -14.7% | 0.04% | -26.8% |
| Q1 2019 | $61,659,000 | +9.2% | 645,505 | -19.0% | 0.06% | -9.7% |
| Q4 2018 | $56,466,000 | -22.1% | 797,200 | -6.0% | 0.06% | -17.3% |
| Q3 2018 | $72,504,000 | -57.4% | 848,400 | -50.8% | 0.08% | -19.4% |
| Q2 2018 | $170,179,000 | +148.9% | 1,723,400 | +104.0% | 0.09% | +24.0% |
| Q1 2018 | $68,361,000 | +51.0% | 844,900 | +9.5% | 0.08% | +50.0% |
| Q4 2017 | $45,277,000 | +42.0% | 771,600 | +13.3% | 0.05% | +31.6% |
| Q3 2017 | $31,875,000 | +42.8% | 681,100 | +9.8% | 0.04% | +35.7% |
| Q2 2017 | $22,326,000 | +27.7% | 620,500 | +9.3% | 0.03% | +16.7% |
| Q1 2017 | $17,485,000 | -9.2% | 567,693 | -1.2% | 0.02% | -20.0% |
| Q4 2016 | $19,255,000 | +3.2% | 574,771 | -18.1% | 0.03% | -9.1% |
| Q3 2016 | $18,664,000 | +456.1% | 701,400 | +360.8% | 0.03% | +450.0% |
| Q2 2016 | $3,356,000 | +105.5% | 152,200 | +173.7% | 0.01% | +100.0% |
| Q1 2016 | $1,633,000 | -50.4% | 55,600 | -33.2% | 0.00% | -66.7% |
| Q3 2014 | $3,295,000 | +40.1% | 83,277 | +52.5% | 0.01% | +80.0% |
| Q2 2014 | $2,352,000 | +34.1% | 54,600 | -15.1% | 0.01% | +25.0% |
| Q4 2013 | $1,754,000 | – | 64,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |